BioStrategics Consulting Ltd   Report issue

For profit Phase 2 Phase 3
Founded: Marblehead MA United States (1999)

Organization Overview

First Clinical Trial
2006
NCT00280917
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Biostrategics Consulting, Ltd. | BioStrategics Consulting Ltd

Active Ingredients

Drugs in Phase 3 Trials (2)

Namodenoson (2 trials)

pexiganan acetate (2 trials)

Drugs in Phase 2 Trials (2)

econazole (spectazole) (1 trial)

ib-meca (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Communicable Diseases (Phase 3)

Diabetic Foot (Phase 3)

Foot Ulcer (Phase 3)

Infections (Phase 3)

Onychomycosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4